Progress of poly (ADP-ribose) polymerase inhibitor in advanced ovarian cancer

VernacularTitle:聚二磷酸腺苷核糖聚合酶抑制剂在晚期卵巢癌中的研究进展
Author: Yuqing CAO ¹ ; Lixin SUN
Author Information

1. 山西医科大学研究生院，太原　030001
Keywords: Ovarian neoplams; Poly (ADP-ribose) polymerase inhibitors; Maintenance therapy; Treatment outcome
From: Cancer Research and Clinic 2023;35(4):317-320
CountryChina
Language:Chinese
Abstract: At present, ovarian cancer is one of the main diseases threatening women's life and health. The mortality ranks first among female reproductive system malignant tumors. Due to the hidden onset, more than 75% of them are at advanced stage once diagnosed. Advanced ovarian cancer is characterized with the Federation International of Gynecology and Obstetrics (FIGO) stage Ⅲ-Ⅳ, very poor prognosis and the 5-year survival rate less than 50%. In recent years, the exploration of maintenance treatment of ovarian cancer is in full swing. A large number of studies show that poly (ADP-ribose) polymerase (PARP) inhibitors are effective in patients with advanced ovarian cancer. Therefore, PARP inhibitors have gradually become an important part for treatment of ovarian cancer, and the indications have also been concerned by clinicians. This paper reviews the application of PARP inhibitors in advanced ovarian cancer.